|Tag||ADCs Cytotoxin with Linkers|
|Description||Brentuximab vedotin is an antibody-drug conjungate (ADC) used for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin acts through targeting tumor cells with CD30 antigen expressed in.|
|Brife Description||ADC, Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL)|
|Synonyms||SGN-35; previously cAC10-vcMMAE; SGN 35; SGN35|
|Application||the treatment of Hodgkin lymphoma and ALCL|
|Current Developer||Seattle Genetics; Takeda Pharmaceutical|
MC-Val-Ala-PBD is a protective group conjugated PBD, PBD bind in the minor groove of DNA.
DM4-SMe can be readily conjugate to the SH group of an antibody to form antibody-drug conjugate (ADC). .
DM1 with a reactive linker SPP, which can react with antibody to make antibody drug conjugate, as a potent EGFR inhibitor and it overcomes resistant to EGFR.
Vc-MMAD consists the ADCs linker(Val-Cit) and potent tubulin inhibitor (MMAD), Vc-MMAD is an antibody drug conjugate.
Mc-MMAE is a protective group conjugated MMAE, MMAE inhibits tubulin polymerization so that it inhibits cell division.
Brentuximab vedotin is an antibody-drug conjungate (ADC) used for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large ce...
Val-Cit-PAB-MMAE is a potent tubulin inhibitor (MMAE), Val-Cit-PAB-MMAE is an antibody drug conjugate.
Vat-Cit-PAB-MMAD is a protective group conjugated MMAD, MMAD is a toxin payload in antibody drug conjugate.